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Ra  dio immunotherapy is one of the most im  por  tant and ef  fec  tive ther  a  pies for B-cell non
Hoddgkin’s lym  phoma treat  ment. To  day, anti CD-20 an  ti  bod  ies la  beled with beta emit  ter
radionuclides are used in ra  dio immunotherapy. Var  i  ous radionuclides for la  bel  ing anti CD-20
an ti bod ies  have  been  stud ied  and  de vel oped  for  the  treat ment  and  di ag no sis  of  ma lig nan cies.
This pa  per de  scribes the prep  a  ra  tion, bio-dis  tri  bu  tion and ab  sorbed dose rate of 111In, 90Y,
177Lu, and 153Sm la beled anti CD-20 an ti bod ies (rituximab) in hu man or gans, af ter in jec tion to
rats.  The macro cy  clic bifunctional che  lat  ing agent, N-succinimidyl-1, 4, 7,
10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA-NHS) for con  ju  ga  tion to an  ti  -
body, was used to pre  pare DOTA-rituximab. The con  ju  gates were pu  ri  fied by mo  lec  u  lar fil  tra  -
tion, the av er age num ber of DOTA con ju gated per mAb was cal cu lated and to tal con cen tra tion
was de  ter mined by spec tro  pho  to met  ric method. Ra  dio-la  bel  ing was per  formed at 40 °C for 24
hours. Af  ter the qual ity  con trol  stud ies,  the  fi nal  ra dio ac tive  so lu tion  was  in jected  in tra ve -
nously into rats through their tail vein. The tis  sue up  takes of each in  jec  tion were mea  sured.
Then we cal  cu  lated S val  ues for 177Lu and 153Sm by us  ing spe  cific ab  sorbed frac  tions and data
used in the man ner of ra dio-la beled anal y sis and do sim e try for hu mans. The ab sorbed dose rate
of each or gan was cal cu lated in the spe cific time by med i cal in ter nal ra di a tion dose method with
lin ear  ap prox i ma tion  in  the  ac tiv ity  mea sure ments.
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IN TRO DUC TION
Ra dio immunotherapy (RIT) is a tar geted ther apy
com bined from im mu nol ogy and ra dio ther apy [1, 2]. In
the United States, ra  dio immunotherapy has been con  -
firmed by FDA for the treat  ment of some kinds of lym  -
phoma. Bexxar (tositumomb) is a la  beled monoclonal
an ti body  with  131I, and Zevalin (ibritumomab tiuxetan)
is a la beled monoclonal an ti body with 90Y. Both of them 
are anti CD-20 monoclonal an  ti  bod  ies [3].
Rituximab,  a  chi me ri cal,  mouse-hu man,  mono-
clonal  an ti body  is  mainly used in the treat  ment of
non-Hodg  kin’s lym  phoma. Like the other com  mon
an ti bod ies  used  against B-cell, rituximab binds with
hu man  B-lym pho cyte-re stricted  dif fer en ti a tion  an ti -
gen: CD-20. CD-20 is not shed from the cell sur  face
and does not in  ter  nal  ize upon an  ti  body bind  ing.
Rituximab is thought to de  plete CD-20-pos  i  tive cells
via an ti body-de pend ent  cell-cytotoxicity and com ple -
ment me  di  ated cell lysis. These prop  er  ties make the
CD-20 re  cep  tor a suit  able tar  get for tar  geted ther  apy.
The up take  of  an ti body  has  been  ob served  on  lym -
phoid  cells  in the spleen, thy mus,  B-lym pho cytes  and
lymph nodes and liver. Rituximab has been used suc  -
cess  fully as an anti CD-20 ra  dio-la  beled an  ti  body [2].
So far, many beta emit ters such as 131I, 90Y, 153Sm, and
177Lu were widely used in var i ous  pre vi ous  stud ies
[4]. Due to an ap  pro  pri  ate half-life and de  cay char  ac  -
ter is tics of these nuclides they can be used in an ti body
la  bel  ing for RIT. Some beta emit  ters de  cay gamma
pho  tons whose en  ergy lev  els are in the range of
SPECT cam  eras. These gamma ir  ra  di  a  tions are fea  si  -
ble for im  ag  ing with treat  ment and us ing  in  di ag nos -
tic/ther a peu tic  stud ies  [3].
Au ger elec tron is an other kind of elec tron ir ra di -
a  tion which is not dif  fer  ent from beta in na  ture, it just
has a dif  fer  ent source and en  ergy. Au  ger elec  trons
have wide en  ergy range from lower than 1 keV to
higher than 100 keV, so some of them can be used in
treat ment  goals  for  mo lec u lar  cat e gory.  111In is an au  -
ger elec  tron emit  ter and due to its gamma ra  di  a  tion
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*  Cor re spond ing  au thor;  e-mail:  ajalili@aeoi.org.irwith suit  able en  ergy, now a days it has a di ag nos tic  use
as  a  tracer nu  clide in treat  ment with Zevalin [5].
Al though the bio-dis  tri  bu  tion of the ra  dio-la  -
beled an ti bod ies is al most the same as bio-dis tri bu tion
of in tact an ti body, but as a bio-con ju gate, the ra dio-la -
beled an  ti  body would go through the met  a  bolic pro  -
cesses in liver, lungs and other met  a  bolic sites lead  ing
to the re lease of free cat ions in the stream. Thus, in the
sec ond  step,  the  cationic  por tion  ac cu mu la tion  would
serve as a new radiochemical spe  cies lead  ing to va  ri  -
ety of bioaccumulation modes based on each
radionuclide. Fi  nally, amount of dose im  posed to the
dif fer  ent or gans is re  lated to the en  ergy and type of ra  -
di a tion for each ra dio iso tope. In the pres ent ar ti cle, the
prep a ra tion  and  bio-dis tri bu tion  of  177Lu,  153Sm,  90Y,
and  111In la  beled anti CD-20 an  ti  bod  ies (rituximab)
con ju gates have been stud  ied and fol  lowed by the cal  -
cu la tion  of  pre lim i nary  do sim e try  for  hu mans,  based
on  dis tri bu tion  data  in  rats  by  ac cept able  ap prox i ma -
tions.  Ta ble  1  dem on strates  phys i cal  prop er ties  of
177Lu,  153Sm,  90Y, and 111In.
METH ODS
111In is pro  duced in cy  clo  trons as a car  rier-free
ra dio iso tope  by  the  pro ton  ir ra di a tion  of  112Cd-en -
riched tar gets through 112Cd(p, 2n)111In  re ac tion.  111In
dis  in  te  grates by the elec  tron cap  ture via the ex  cited
level of 416.6 keV in 111Cd. 111In was pro  duced at the
Ag ri cul tural,  Med i cal  and  In dus trial  Re search  School
(AMIRS) 30 MeV cy  clo  tron (Cy  clone-30, IBA)
Karaj, Iran [6, 7].
90Y is ob  tained from the nat  u ral de  cay of its par  ent
in  90Sr (t1/2 = 29 years) gen  er  a  tor and is sep  a  rated
radiochemically from 90Sr by a se ries of pre cip i ta tion and 
fil tra tion steps, or us ing a set of stron tium-se lec tive chro -
mato graphic  col umns.  Ob tained  90Y is a car  rier free ra  -
dio iso tope for the nu clear med i cine from a re search lo cal
gen er a tor.  90Y de  cays with a phys  i  cal t1/2 of 64 hours by
b– emis sion to sta ble 90Sr [8, 9] or can be pro duced in low 
spe cific  ac tiv ity  by  neu tron  ac ti va tion  [10].
153Sm is a re  ac  tor prod  uct. 153Sm was pro  duced
by the ther mal neu tron ir ra di a tion of en riched tar get of
152Sm with 4×1013 cm–2s–1 neu  tron flux for 3 days at
Teh ran  Re search  Re ac tor.  153Sm is pro  duced ac  cord  -
ing to the re  ac  tion 152Sm(n, g)153Sm by s = 206 b for
ther mal neu tron and dis in te grates via 3 main routes by
100% b– emis sion to lev els in 153Eu. 153Sm is not a car -
rier free ra  dio  iso  tope and its spe  cific ac  tiv  ity was
14.5-17 GBq/mg. 177Lu is re  ac  tor-pro  duced by the
ther mal  neu tron  ir ra di a tion  of  176Lu en  riched tar  gets
with the re  ac  tion 176Lu(n, g)177Lu with s = 2020 b.
177Lu was ob  tained by ex  po  sure of nat  u  ral Lu2O3
(175Lu: 97.5% and 176Lu: 2.5%) sam ple with a spe cific
ac  tiv  ity of 2.6-3 GBq/mg and radionuclide pu  rity of
99.98% , to ther  mal neu  tron flux  4×1013 cm–2s–1  for 5
days  at  Teh ran  Re search  Re ac tor.  The  ir ra di a tion  tar -
gets were dis solved in 200 µL of 1.0 M HCl, in or der to 
pre pare  177LuCl3 and 153SmCl3.
Chem  i  cals were pur  chased from Sigma-Aldrich
Chem i cal Co. (UK). NHS-DOTA was pur chased from
Macrocycles (USA). Rituximab (Mabthera) was a
phar ma ceu ti cal sam ple pur chased from Roche Co. Ra -
dio-chro ma tog ra phy  was  per formed  by  us ing  a
Bioscan AR-2000 ra  dio TLC scan  ner in  stru  ment
(Bioscan, Paris, France). A high pu  rity ger  ma  nium
(HPGe) de  tec  tor cou  pled with a Can  berra™ (model
GC1020-7500SL)  mul ti chan nel  an a lyzer  and  a  dose
cal  i  bra  tor ISOMED 1010 (Dresden, Ger  many) were
used for count ing dis trib uted ac tiv ity in rat or gans. All
val  ues were ex  pressed as mean ±  stan dard  de vi a tion
(Mean  ± SD) and the data were com  pared us  ing stu  -
dent’s  T-test.  Sta  tis  ti  cal  sig  nif  i  cance  was  de fined as
P < 0.05. An  i  mal stud  ies were per  formed in ac  cor  -
dance with the United King  dom Bi  o  log  i  cal Coun  cil’s
Guide  lines on the Use of Liv  ing An  i  mals in Sci  en  tific
In ves ti ga tions,  2nd ed.
Prep a ra tion  of  ra dio-la beled
anti  CD-20  an ti bod ies  (rituximab)
The ra  dio-la  bel  ing of all ra  dio-immunoconjugates
are al  most the same, this was men  tioned in the re  lated
sec  tion. In the first step, lyophilized ritiximab (Roche)
was pu  ri  fied with wa  ter for in  jec  tion from ex  cipi  ents by
ul tra-fil tra tion. Vivaspin-2 fil ters (30 kDa; Sar to rius AG;
2 ´ 10 min ute at 2.684 g) were used for all ul tra-fil tra tion
pu ri fi ca tion steps.  In short, trastuzumab was di luted with 
0.2 M Na2CO3 (pH 9.2) buffer so  lu  tion. The an  ti  body
con cen tra tion  was  mea sured  us ing  a  biophotometer
(Eppendorf) at OD = 280 nm. The so  lu  tion was passed
through a Vivaspin 2 (20 min  ute, 2.684 g) two times in
or der to re move the im pu ri ties. The an ti body then can be
re moved from the up per part of the fil ter us ing bi car bon -
ate buffer (0.2 M Na2CO3, pH 9.2). The fi  nal con  cen  tra  -
tion was re-mea sured us ing biophotometric as say as well 
as struc  ture in  teg  rity test us  ing SDS-PAGE. Then
DOTA-NHS (1.3 mg, ex  cess 120 times) dis  solved in bi  -
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Ta ble 1. Phys i cal prop er ties of 
177Lu, 
153Sm, 
90Y, and 
111In
b-maximum
energy
[keV]
Probability
[%]
Gamma
energy
[keV]
Probability
[%]
177Lu
Half-life: 
6.73 (d)
176.5
248.5
384.8
497.8
12.20
0.05
9.10
78.60
71.65
112.95
136.7
208.37
249.67
321.32
0.15
6.40
0.05
11.06
0.21
0.22
153Sm
Half-life:
1.92 (d)
635
705
808
32.2
49.6
17.5
69
103
4.85
29.8
90Y
Half-life:
2.67 (d)
2280
519.1
99.98
0.01 1760.7 0.01
111In
Half-life:
2.81 (d)
– 100 171.25
245.3
100
100car bon ate buffer (400 µl, 0.2 M, pH 9.2) was added to the 
pu  ri  fied an  ti  body so  lu  tion  (3.3 mg/ml) in a boro  sili  cate
vial and mixed gently for 20 times by pipetting. The mix -
ture was gently shaken and in  cu  bated at room tem  per  a  -
ture for 24 hours. The mix  ture was then trans  ferred on a
Vivaspin 2 cut-off  fil  ter (30 KD) and cen  tri  fuged at
2.684 g for 15 min utes. In or der to ter mi nate the con ju ga -
tion step and pro  vide the suit  able radiolabeling pH, the
up per fil ter frac  tion is washed through us ing am mo nium
ac  e  tate buffer (0.2 M, pH 5.5) three times in or  der to re  -
move ex cess of DOTA-NHS. In this stage, ac e tate buffer
(1 ml) is added to the up  per frac  tion, and the mix  ture is
pippeted 10-20 times for immonoconjugate dis  so  lu  tion.
The fil  ter is then cen  tri  fuged up  side-down at 2.684 g for
5  min ute.  The  an ti body  con cen tra tion  was  mea sured  us -
ing a biophotometer (Eppendorf) at OD = 280 nm. The
spec tro pho to met ric  method  for  quantitation  of
micromolar con  cen  tra  tions of bifunctional DOTA-NHS
ligand in DOTA-monoclonal an  ti  body (mAb) con  ju  -
gates is per  formed ac  cord  ing to the re  ported method
[11]. Briefly, the op  ti  cal den  sity of arsenaso yt  trium (III)
com  plex (2:1, 1 ml), pre  pared in 5.0 µM AAIII, 1.6 µM
Y(III), 0.15 M so dium ac e tate buffer, pH 4.00, was mea -
sured at 652 nm.  A stan  dard curve was then plot  ted by
the ad di tion of mul ti ple (8 ´) 15 µl DOTA-NHS stan dard 
so lu tions (DOTA-NHS dis solved in 0.15 M so dium ac e -
tate buffer, pH 4.00), to the above mix  ture. In the sec ond
step, the op  ti  cal den  sity of 1:2 yt  trium (III) com  plex of 
arsenaso (1 ml) was mea  sured at 652 nm in the pres  ence
of  con ju ga tion  prod uct  in  or der  to  de ter mine  DOTA-an -
ti body  at tach ments.  For  radiolabeling,  typ i cally,  370
MBq of ra  dio  iso  tope dis  solved in 0.2 M HCl was added
to a con i cal vial and dried un der a flow of ni tro gen. To the 
cop  per-con  tain  ing vial ac  e  tate buffer (700 µl, pH 5.5)
was added and the vial swirled for 10 min  utes. The con  -
ju gate con tain ing frac tion (500 µg) in ac e tate buffer with
the mea  sured pro  tein con  tent was added to the vial and
mixed gently for 5 min  utes us  ing pipetting (10-20 ´).
The mix ture is then in cu bated at 40 ºC for 90 minutes fol -
lowed by test ing the radiochemical pu rity by ITLC us ing
a ra dio TLC scan ner (Whatman No. 1, 1 mM DTPA). Fi -
nally ETDA so  lu  tion (10 µl, 10 mM) is added to the la  -
bel  ing mix  ture and in  cu  bated for 10 minutes in or  der to
scav  enge the unlabeled Cu cat  ion. The mix  ture is then
passed through the dis  pos  able PD10 De-salt  ing col  umn
(Amersham) in or  der to fur  ther in  crease the
radiochemical pu rity of the mix ture. The fi nal so lu tion is
then passed through a 0.22 mi  cron bi  o  log  i  cal fil  ter for
an  i  mal stud  ies. The ra  dio-immunoconjugate was an  a  -
lyzed for in  teg  rity by SDS-polyacrylamide gel elec  tro  -
pho re sis (SDS-PAGE). The ra dio la beled mAb was eval -
u  ated with and with  out re  duc  tion by 2-mercaptoethanol.
Ap prox i mately 200 000 cpm of each prep a ra tion was ap -
plied per lane and the 4-20% polyacrylamide were run
ac  cord  ing to the method of Laemmli [12]. The fi  nal
radiochemical pu rity of the ra dio la beled monoclonal an -
ti  bod  ies was checked by RTLC and HPLC as de  scribed
ear  lier and in all cases it was >95% [4].
Bio-dis tri bu tion  data
177Lu-DOTA-rituximab,  90Y-DOTA-rituximab,
153Sm-DOTA-rituximab, and 111In-DOTA-rituximab
were ad  min  is  tered to the nor  mal rats sep  a  rately (15
rats) in or  der to de  ter  mine bio-dis  tri  bu  tion. A vol  ume
(50-100 mL) of  fi  nal  ra  dio  ac  tive  so  lu  tion  with 3.7 ±
±.0.1 MBq ac  tiv  ity was in  jected in  tra  ve  nously to the
rats through their tail vein. The an  i  mals were killed at
the ex act time (3 rats in each time) and the spe cific ac -
tiv  i  ties of dif  fer  ent or  gans were mea  sured by us  ing an
HPGe de tec tor (for  177Lu,  111In, and 153Sm) and a beta
scin til la tion de tec tor (for  90Y). Then the per cent age of
in  jected dose per gram (%ID/g) for each or  gan was
cal  cu  lated in each time point. It is nec  es  sary to cal  cu  -
late the %ID/g, since there are in  her  ent lim  i  ta  tions in
mea sur ing the ac tiv ity of all tis sues of each or gan, such 
as bone and blood.
The fol  low  ing equa  tion was used to ex  trap  o  late
bio-dis tri bu tion data of ra dio la beled com pounds from 
rats to hu  mans
% % ID
g
ID
g human organ animal organ
= k (1)
k =
Body mass
Body mass
animal
human
(2)
The equa  tion shows that the bio-dis  tri  bu  tion ra  -
tio of ac  tiv  ity per each gram of each or  gan in the rat
and hu  man is a con  stant value which de  pends on the
to  tal tis  sue weight to body weight for rat and for hu  -
mans. The above equa tion is ob tained from the fol low -
ing equa  tion with an al  ge  braic for  mula [13]
% % ID ID
Organ mass  
Body
human organ animal organ
human
=
 mas
Organ mass  
Body  mas
human
animal
animal
(3)
Dose  es ti mates
Be fore  ther a peu tic  or  in ves ti ga tion  use on hu  -
mans, some knowl  edge of the ab  sorbed dose for pa  -
tients is es sen tial  in  ra dio ther apy.  Med i cal  in ter nal  ra -
di  a  tion dose (MIRD) method is a stan  dard one for
cal  cu  lat  ing the dose es  ti  mates when radionuclides en -
ter the hu man body and ac cu mu late there. This method 
is based on the ab  sorbed frac  tions (j) and spe cific ab -
sorbed frac  tions of en  ergy (F) [14]. 
   D r r A S r r ( )[ ]
~
[ ] ( ) k h h k h mGy MBqs ¬ = ¬ (4)
  S r r r r k h i i k h ( )[ ] ( )
– ¬ =å ¬ mGyMBq s
–1 1 D F (5)
Di i i n E [ ] . [ ]
– – kg mGyMBq s MeV
–1 1 13 16 10 = × (6)
F =
j
m
(7)
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ted en  ergy of source which is ab  sorbed in place of the
tar  get or  gan. In or  der to cal  cu  late the dose es  ti  mates
based on this method, we should mea  sure the cu  mu  -
lated ac  tiv  ity in each or  gan as a source of ra  di  a  tion. 
Bio-dis tri bu tion data for hu man was de ter mined
by eq.1 based on dis tri bu tion data in rats. There is a lin -
ear equa  tion be  tween ID and in  jected ac  tiv  ity (IA), so
%ID = %IA
There fore %ID can be used for cal  cu  lat  ing the
dose es  ti  mates in  stead of %IA when %ID/g (or
%IA/g) was cal  cu  lated in terms of ini  tial in  jec  tion
ac tiv ity  val ues.  In  or der  to  cal cu late  the  cu mu lated
ac  tiv  ity ac  cu  rately for each or  gan, it is es  sen  tial to
know the pharmacokinetic model of each ra  dio la  -
beled com  pound. The pharmacokinetic model for
each  or gan  is  based  on  com pli cated  math e mat i cal
func  tion forms. These func  tions are of  ten multi-ex  -
po  nen  tial ones for the an  ti  bod  ies [15]. In this study,
the re search ers used a lin ear ap prox i ma tion be tween 
the two ex  per  i  men  tal points of times in which the
%ID/g had been mea sured be fore. In or der to re duce
the er  ror of the method, the ex  per  i  men  tal points
should be in  creased.
The to  tal ac  tiv  ity of each or  gan in each time
point, is equal to %ID/g of the or  gan mul  ti  plied by
the mass of or gan. In this study, the mean weights for 
hu  man or  gans with stan  dard weight (70 kg) were
used [16-18]. The au  thors point out that the or  gan
weights vary in dif  fer  ent sexes, races, and other in  -
di vid ual  pa ram e ters.  The  pres ent  study  re stricts  it -
self to a gen  eral stan  dard case shown in tab. 2 [19,
20]. 
RE SULTS  AND  DIS CUS SION
Bio-dis tri bu tion
Ab sorp tion  and bio-dis tri bu tion  of  ra dio  la beled
com pounds in or gans of rats were de ter mined by mea -
sur ing %ID/g at dif  fer  ent times. The up takes  were  ob -
served  in the lim  ited or  gans such as the liver, spleen
and lungs and barely in the kid  neys, bone and blood.
Cu mu lated  ac tiv ity
Bio-dis  tri  bu  tion data for hu  mans were de  ter  -
mined by eq. 1 based on the dis  tri  bu  tion data in rats.
The ac tiv ity value in hu man or gans with lin ear ap prox -
i ma tion  was  cal cu lated  and  rep re sented  di a gram mat i -
cally as in the fol  low  ing charts.
The cu mu lated ac tiv ity in each or gan for 100 Bq
of each radionuclide in  jec  tion was shown in the fol  -
low ing ta ble (for  111In and 90Y in 72 hours, 153Sm in 48
hours, and 177Lu in 168 hours).
Dose  es ti mates
S val  ues for 111In and 90Y were adopted from
MIRD pam phlet no. 11 [21], then S val ues were cal cu -
lated for 177Lu and 153Sm by us  ing spe  cific ab  sorbed
frac  tions [22], af  ter that the ab  sorbed dose rate in the
spe  cific time for var  i  ous or  gans was cal  cu  lated. In or  -
der to cal  cu  late S val  ues of 177Lu and 153Sm, the re  -
search ers used the spe cific ab sorbed frac tions for each
gamma and beta en  ergy of these radionuclides for any
source/tar  get or  gan. The spe  cific ab  sorbed frac  tions
for beta de cays will be 1, if both the source and the tar -
get re fer to only one or gan, oth er wise they will be zero. 
S val  ues (for some source or  gans) of 153Sm and 177Lu
which were cal  cu  lated in the ar  ti  cle are shown in the
tabs. 4 and 5
The point is that since blood flows through the
hu man bod ies, then its ac tiv ity is con sid ered as the part 
of ac  tiv  ity of the car  cass.
The sums of ab  sorbed dose rates in spe  cific time
for each or  gan from up  takes of each ra  dio la  beled
com pounds  are  dem on strated  in  the  fol low ing  ta ble.
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Ta  ble 2. The stan  dard weights of or  gans for hu  mans
with stan  dard weight
Organ Mass [g]
Adrenals 14
Blood 5500
Bone 10000
Kidneys 310
Liver 1800
Lungs 1000
Ovaries 11
Pancreas 100
Red marrow 1500
Spleen 180
Stomach wall 150
Thyroid 20
Total body 70000
Ta  ble 3. Cu  mu  lated ac  tiv  ity in each or  gan for 100 Bq
Source
of
activities
111In
in 72
hours
[Bq]
90Y
in 72
hours
[Bq]
153Sm
in 48
hours
[Bq]
177Lu
in 168
hours
[Bq]
Liver 1.00E+07 7412794 6240141 1.50E+07
Spleen 1273493 486673 354265 1799396
Kidney 356347 32971.1 132562 91604
Lung 2314346 5674364 1001479 2681656
Bone 61873.7 1307319 1740421 5188390
Blood 649794 606337 227472 849008In the pres ent study, the re search ers in ves ti gated
four ra  dio la  beled anti CD-20 an  ti  bod  ies (rituximab)
and  stud ied  the  prep a ra tion,  QCs  and  bio-dis tri bu tion
of them in the nor  mal rats. Bio-dis  tri  bu  tions of ra  dio
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Fig  ure 1. Biodistribution of radiolabeled in the or  gans of rats
Fig  ure 2. The ac  tiv  ity value in hu  man organsla  beled com  pounds were in agree  ment with other ra  -
dio la  beled anti CD-20 an  ti  bod  ies  spe  cies al  ready re  -
ported [23, 24], more  over, they were in line with our
pre vi ous  stud ies.
High up  take in the spleen and reticoloendo-
thelial or  gans due to the fi  nal ac  cu  mu  la  tion of B-lym  -
pho cytes  car ry ing  the  ra dio-immunoconjugate  on
their sur face was ob served. As a nat u ral re ac tion to the
de  ple  tion of the lym  pho  cytes, the reticulloendothelial
sys  tem in  clud  ing the spleen will be the fi  nal pos  si  ble
res er voir of the de pleted lym pho cytes. Ob serv able ac -
cu  mu  la  tion in the lungs was also ob  served. In  ter  est  -
ingly, we found re ports of se  vere pul mo nary re  ac  tions
(pul  mo  nary in  fil  trates or edema) dur  ing anti CD-20
an ti bod ies    ther apy  in  the  lit er a ture  [4],  [25-27]
The ab sorbed dose rate of each or gan was cal cu -
lated in the spe  cific time by MIRD method with the
lin ear  ap prox i ma tion  of  mea sure ment  of  ac tiv i ties.
The dose rate es  ti  ma  tion is based on more than 1.5
times of ef  fec  tive half-life of each ra  dio la  beled com  -
pound.
The re  sults showed that the high ab  sorbed dose
is in the liver, lungs and spleen; and the ab  sorbed dose
of other or  gans (such as the red mar  row and brain) is
low as ac cept able  level  val ues.
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Ta ble  4.  S val  ues of 
177Lu [mGyMBq
–1s
–1]
Target \ Source Liver Spleen Kidneys Lungs Bone Carcass
Adrenals 1.02E-07 1.06E-07 1.68E-07 5.54E-08 5.81E-08 3.74E-07
Bladder wall 8.70E-08 2.68E-09 1.88E-09 9.05E-08 8.65E-09 3.71E-07
Bone surfaces 2.43E-08 2.47E-08 3.17E-08 3.26E-08 2.47E-06 3.86E-07
Brain 2.40E-10 1.96E-10 4.87E-11 2.02E-09 2.80E-08 3.63E-07
Breasts 1.65E-08 1.09E-08 5.12E-09 5.40E-08 1.27E-08 3.58E-07
Stomach wall 3.44E-08 1.75E-07 5.87E-08 2.76E-08 1.99E-08 3.69E-07
Heart wall 5.46E-08 3.76E-08 1.89E-08 1.02E-07 2.59E-08 3.73E-07
Kidneys 6.84E-08 1.52E-07 7.82E-05 1.66E-08 1.56E-08 3.71E-07
Liver 1.37E-05 1.74E-08 6.78E-08 1.88E-08 1.18E-08 3.71E-07
Lungs 1.26E-08 3.95E-08 1.88E-07 2.39E-05 1.71E-08 3.66E-07
Ovaries 9.23E-09 9.70E-09 1.69E-08 1.26E-09 1.23E-08 3.75E-07
Pancreas 8.83E-08 2.98E-07 1.16E-07 3.96E-08 3.55E-08 3.76E-07
Red marrow 2.01E-08 2.05E-08 4.14E-08 6.24E-08 2.45E-06 3.68E-07
Skin 8.67E-09 8.56E-09 9.43E-09 9.72E-09 1.03E-08 3.56E-07
Spleen 1.73E-08 1.35E-04 1.52E-07 1.78E-08 1.10E-08 3.71E-07
Testes 6.25E-10 6.60E-10 9.35E-10 1.28E-10 1.12E-08 3.65E-07
Thyroid 2.34E-09 2.08E-09 9.61E-10 4.56E-09 1.54E-08 3.69E-07
Uterus 7.96E-09 6.67E-09 1.53E-08 1.18E-09 3.66E-08 3.76E-07
Total body 3.74E-07 3.71E-07 3.68E-07 3.74E-07 3.66E-07 3.66E-07
Ta ble  5.  S val  ues of 
153Sm [mGyMBq
–1s
–1]
Target \ Source Liver Spleen Kidneys Lungs Bone Carcass
Adrenals 1.69E-07 1.87E-07 2.81E-07 8.72E-08 8.61E-08 5.83E-07
Bladder wall 3.65E-09 2.07E-09 6.11E-09 6.50E-10 1.39E-08 5.81E-07
Bone surfaces 6.00E-08 6.16E-08 7.92E-08 8.80E-08 3.93E-06 6.47E-07
Brain 1.70E-10 5.39E-11 2.87E-11 2.10E-09 3.98E-08 5.68E-07
Breasts 2.41E-08 1.47E-08 5.80E-09 8.77E-08 1.86E-08 5.56E-07
Stomach wall 5.45E-08 3.18E-07 9.50E-08 4.50E-08 2.73E-08 5.73E-07
Heart wall 8.88E-08 6.39E-08 2.77E-08 1.75E-07 3.80E-08 5.81E-07
Kidneys 1.15E-07 2.63E-07 1.22E-04 2.23E-08 3.02E-08 5.77E-07
Liver 2.14E-05 2.39E-08 1.12E-07 7.39E-08 2.02E-08 5.78E-07
Lungs 7.78E-08 6.77E-08 2.34E-08 3.75E-05 3.04E-08 5.74E-07
Ovaries 1.18E-08 1.05E-08 2.23E-08 1.71E-09 3.49E-08 5.84E-07
Pancreas 1.48E-07 5.23E-07 1.97E-07 6.74E-08 5.05E-08 5.86E-07
Red marrow 2.81E-08 2.90E-08 5.96E-08 5.48E-08 3.84E-06 5.69E-07
Skin 1.29E-08 1.25E-08 1.34E-08 1.43E-08 1.43E-08 5.53E-07
Spleen 2.35E-08 2.10E-04 2.63E-07 6.67E-08 1.80E-08 5.77E-07
Testes 1.06E-09 4.52E-10 6.66E-10 1.05E-10 1.54E-08 5.66E-07
Thyroid 2.37E-09 2.30E-09 5.17E-10 2.76E-08 2.07E-08 5.76E-07
Uterus 1.01E-08 7.30E-09 1.98E-08 9.25E-10 5.29E-08 5.85E-07
Total body 5.81E-07 5.80E-07 5.79E-07 5.75E-07 5.76E-07 5.72E-07CON CLU SIONS
There fore, ac cord ing to the kind of de cay and en  -
ergy (only b–, >2 MeV), it is ob  served that 90Y im  pose
the high  est amount of ab  sorbed dose to the body; the
lungs (with the 42% of the to  tal dose) re  ceive a dose
more than 8.5 mGy/MBq in 72 hours. The liver, spleen
and red mar  row with 6.1, 4.0, 0.5 (3%) mGy/MBq, re  -
spec  tively, have the high  est amount of ab  sorbed dose.
The other or  gans re  ceive the dose less than 5% of to  tal
one.
As the re  search  ers ex  pected, due to the high  est
abun dance of  gamma pho  ton de  cay, 111In has the larg -
est share in or  gans that re  ceived dose. The liver and
spleen re  ceived the dose about 1 mGy/MBq (around
30% of to tal one) in 72 hours. The ab sorbed dose of the 
lungs, kid  neys, pan  creas, and ad  re  nals were 0.31,
0.26, 0.17, and 0.16 mGy/MBq, re  spec  tively. In com  -
par i son to  90Y,  111In im poses lower dose to the pa tients
as  a  di ag nos tic/ther a peu tic  radionuclide.
For  153Sm in 48 hours, the high  est ab  sorbed dose
was ob served in the liver with 1.3 mGy/MBq (46%) fol -
lowed by the spleen,  lungs, kid neys,  and  bone  tis sues
re ceived 0.74 (26%), 0.38 (13%), 0.17 (6%), and 0.07
(3%) mGy/MBq,  re spec tively.
177Lu had the small est  share in or  gans that re  -
ceived dose. The high  est ab  sorbed dose was ob  served
in the spleen with 2.5 mGy/MBq (42%), and in the
liver with 2.1 mGy/MBq (37%) in 168 hours. The
lungs com  prised the only tis  sues that re  ceived more
than 3% of to tal dose with 0.64 mGy/MBq (11%). The
re  sults showed that 177Lu con trib utes more to dose
than  153Sm, so it can be said that the main rea son is lon -
ger half-life of 177Lu in  com par i son  with  153Sm.
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UPOREDNO  PROU^AVAWE  PRELIMINARNE  HU  MANE
DOZIMETRIJE  ZASNOVANO  NA  RASPODELI  ANTITELA
U  PACOVA  MARKIRANIH  111In, 90Y, 177Lu, I 153Sm
Radioimunoterapija je jedna od najva`nijih i najefektivnijih terapija za le~ewe
B-}elija ne-Ho~kinovog limfoma, te se danas u woj koriste anti-CD20 antitela markirana sa
radionuklidima koji su beta emiteri. Ovaj rad prikazuje pripremu, bioraspodelu i ja~inu
aposorbovane doze anti-CD20 antitela (rituksimab) markiranih 111In, 90Y, 177Lu, i 153Sm. U
pripremi  DOTA-rituximab-a za potrebe vezivawa sa antitelima kori{}ena je N-succinimidyl-1, 4, 7,
10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic kiselina (DOTA-NHS) koja je makro-cikli~ni ~elatin
agens. Kowuganti su pro~i{}eni molekularnom filtracijom, izra~unat je sredwi broj DOTA-e
kowugovane i odre|ena ukupna koncentracija primenom spektrofotometrijske metode.
Radiomarkirawe je trajalo 24 sata pri temperaturi od 40 °C. Posle sprovedene kontrole kvaliteta, 
finalni radioaktivni rastvor je ubrizgan pacovima kroz venu na repu. Merena je prihva}ena
koli~ina rastvora u tkivu posle svakog ubrizgavawa. Potom su izra~unate S vrednosti za 177Lu i
153Sm koriste}i specifi~ne apsorbovane frakcije i podatke kao pri analizi i dozimetriji ra  -
dio-markera kod qudi. Apsorbovana ja~ina doze odre|ena je za svaki or  gan u specifi~nom
vremenskom intervalu koriste}i medicinsku in  ternu radijacionu dozu sa linearnom
aproksimacijom za merewa aktivnosti.
Kqu~ne re~i: radioimunoterapija, bioraspodela, rituksimab, dozimetrija, medicinska
.........................interna radijaciona doza